Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST
23 March 2023 - 11:30PM
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the
“Company”), a developer of Next Generation Chemotherapy drugs that
provide a better safety-efficacy profile than their widely used
FDA-approved counterparts, today announced that it will host a
conference call and live webcast on March 30, 2023 at 4:30 p.m. EST
to discuss its 2022 results and provide an update on its clinical
pipeline for 2023.
Conference Call Information
To participate in this event, please log-on or
dial-in approximately 5 to 10 minutes before the beginning of the
call.
Date: March 30, 2023Time: 4:30 p.m. ETToll Free:
888-506-0062International: 973-528-0011Entry Code: 382258Live
Webcast: https://www.webcaster4.com/Webcast/Page/2572/47882
Conference Call Replay InformationToll-free:
877-481-4010International: 919-882-2331Replay Passcode: 47882Replay
Webcast: https://www.webcaster4.com/Webcast/Page/2572/47882
About Processa Pharmaceuticals,
Inc.
The mission of Processa is to develop the Next
Generation Chemotherapies (with existing clinical evidence of
safety and efficacy) for cancer patients who need better cancer
drugs to extend survival and/or improve their quality of life. The
Company uses its Regulatory Science Approach and the principles of
the FDA’s Project Optimus Oncology initiative to provide an
efficient development program, increase the probability of
approval, and provide a safer and better cancer treatment that can
be easily differentiated from what is presently on the market and
in development. Processa is developing three Next Generation
Chemotherapy oncology treatments: Next Generation Capecitabine
(PCS6422 and Capecitabine to treat metastatic colorectal,
gastrointestinal, breast, pancreatic, and other cancers), Next
Generation Gemcitabine (PCS3117 to treat pancreatic, lung, ovarian,
breast, and other cancers), and Next Generation Irinotecan (PCS11T
to treat lung, colorectal, gastrointestinal, pancreatic, and other
cancers).
For more information, visit the company’s
website at www.processapharma.com.
Forward-Looking Statements
This release contains forward-looking
statements. The statements in this press release that are not
purely historical are forward-looking statements which involve
risks and uncertainties. Actual future performance outcomes and
results may differ materially from those expressed in
forward-looking statements. Please refer to the documents filed by
Processa Pharmaceuticals with the SEC, specifically the most recent
reports on Forms 10-K and 10-Q, which identify important risk
factors which could cause actual results to differ from those
contained in the forward-looking statements.
For More Information:
Michael
Floyd301-651-4256mfloyd@processapharma.com
Patrick Lin(925)
683-3218plin@processapharma.com
Processa Pharmaceuticals (NASDAQ:PCSA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Processa Pharmaceuticals (NASDAQ:PCSA)
Historical Stock Chart
From Jul 2023 to Jul 2024